Effects of Exercises in MS on Postural Control With Dual Task (MScombined)

October 25, 2018 updated by: Melda Soysal Tomruk, Dokuz Eylul University

Effects of Combined Exercises on Postural Control With and Without Dual Task in Patients With Multiple Sclerosis

Multiple sclerosis is a progressive neurological disease that associated with demyelinization and axonal damage. Decreased postural control is one of the initial symptom of disease. Improving postural control in people with neurological impairment is a common goal of physiotherapy. Doing exercises in water or land are examples for effective solutions. Pilates and aquaplyometric exercises are some of these approaches.

Performing daily activities at the same time requires dual tasking or multi tasking. Dual tasking is frequently impaired in MS. The aim of the study was to determine effect of combined Pilates and Aquaplyometric exercises on postural control with or without dual task in patients with multiple sclerosis.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

MS patients with decreased postural control will be enrolled eight-week, 45 minutes combined Pilates and aquaplyometric exercise programme. Postural control, hand dexterity and other functional parameteres will assess besaline and at the eighth week of exercise programme by the physiotherapist. Postural control will evaluate with and without dual task.

Study Type

Interventional

Enrollment (Anticipated)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Balçova
      • İzmir, Balçova, Turkey, 35330
        • Recruiting
        • Dokuz Eylul University, School of Physical Therapy and Rehabilitation
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • being over 18 years old
  • ability to walk independently or with single walking aid
  • having stable symptoms

Exclusion Criteria:

  • being acute or unstable phase of disease
  • having EDSS score>6
  • insuitable for the pool (incontinance, dermatological disease etc.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in limits of stability parameter with Biodex Balance System
Time Frame: Baseline and 8 weeks
measured with Biodex Balance System (BBS; SD 12.1"Display 115 VAC). Patients were asked to stand on the rigid surface with barefoot and eyes open during measuring limits of stability. During each test trial, patients must shift their weight to move the cursor from the center target to a blinking target and back as quickly and with as little deviation as possible. The same process is repeated for each of the nine targets. Targets on the screen blink in random order. The tests repeated three times with 30 second resting time between trials. Patients' performance is evaluated from a total score of 100 where the higher score represents better trunk control.
Baseline and 8 weeks
Change in limits of stability parameter with cognitive task by Biodex Balance System
Time Frame: Baseline and 8 weeks
Patients are asked to perform previously explained test protocol while maintaining balance they need to count down three-by-three from a randomly selected two-digit number. . Patients' performance is evaluated from a total score of 100 where the higher score represents better trunk control.
Baseline and 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Nine hole peg Test
Time Frame: Baseline and 8 weeks
The patient is seated at a table with a plastic NHPT placed at the patient's middle and asked to place pegs in a random order as quick as possible by using dominant hand first total time was recorded in seconds. Three consecutive trials with the dominant hand are immediately followed by three consecutive trials with the non-dominant hand.
Baseline and 8 weeks
Change in timed up and go test
Time Frame: Baseline and 8 weeks
test was used to assess mobility and static and dynamic balance. The starting point was determined after the patient had been seated in a standart height chair with their back flush against the chair and their arms resting on the arm rests. The patients asked to stand up, walk three meters, turn around, walk back to the chair and sit down again. During the test the patients was expected to wear their regular footwear and use any mobility aids that they would normally require. Timing began when the patient started to rise and ended when returned to the chair and sit down. Lower time score represents better mobility and balance.
Baseline and 8 weeks
Change in 5-Repetititon Sit-To-Stand Test
Time Frame: Baseline and 8 weeks
test is a meaure of the time taken to complete five repetitions of the STS movement. The patients were told to start the test in a seated position with full weight on the chair and arms folded across the chest. The feet were placed parallel to each other. The patients asked to move to a standing position with full knee extention and then back to a seated position as quickly as possible. After completion of five repetitions the test ended when patient touched the seat. Lower time score represents better lower extremity muscle strength
Baseline and 8 weeks
Change in timed 25 step walking test
Time Frame: Baseline and 8 weeks
The patients were directed to one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly as possible but safely. The time was calculated from the initiation of the instruction to start and ended when the patient had reached the 25-foot mark. Lower time score represents better walking or mobility performance
Baseline and 8 weeks
Handgrip strength test
Time Frame: Baseline and 8 weeks
The patient was seated at a table and the subject holded the dynamometer in the dominant hand with the arm at right angles (90˚ flexion) and the elbow by the side of the body. The handle of the dynamometer was adjusted as the base should rest on first metacarpal, while the handle should rest on middle of four fingers. When ready the patient asked to squeeze the dynamometer with maximum isometric effort, which was maintained for about 5 seconds. Three consecutive trials were done and higher score was recorded (25). Higher score represents better grip force.
Baseline and 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Barış Gürpınar, PhD, Dokuz Eylül University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2018

Primary Completion (Anticipated)

November 30, 2018

Study Completion (Anticipated)

November 30, 2018

Study Registration Dates

First Submitted

October 16, 2018

First Submitted That Met QC Criteria

October 23, 2018

First Posted (Actual)

October 24, 2018

Study Record Updates

Last Update Posted (Actual)

October 29, 2018

Last Update Submitted That Met QC Criteria

October 25, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

via clinical study

IPD Sharing Time Frame

in 2 years

IPD Sharing Supporting Information Type

  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on exercise

Subscribe